Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities: 2021-2024

Historic Cash from Investing Activities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $75.7 million.

  • Amylyx Pharmaceuticals' Cash from Investing Activities fell 86.51% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.6 million, marking a year-over-year increase of 56.81%. This contributed to the annual value of $75.7 million for FY2024, which is 17.81% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Cash from Investing Activities stood at $75.7 million for FY2024, which was down 17.81% from $92.1 million recorded in FY2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Cash from Investing Activities peaked at $92.1 million during FY2023, and registered a low of -$239.0 million during FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was $75.7 million (2024), whereas its average is -$23.8 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Cash from Investing Activities tumbled by 414.99% in 2022, and later spiked by 138.52% in 2023.
  • Over the past 4 years, Amylyx Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$46.4 million in 2021, then crashed by 414.99% to -$239.0 million in 2022, then soared by 138.52% to $92.1 million in 2023, then declined by 17.81% to $75.7 million in 2024.